Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Exclusion Criteria

• •Received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy.
• •Diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study.
• •Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Active autoimmune disease.
• •Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.
• •Active infection requiring systemic therapy.
• •Known history of human immunodeficiency virus (HIV).
• •Active or chronic hepatitis B or hepatitis C.
• •Known active tuberculosis.
• •History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc.
• •Prior allogeneic stem cell transplantation or organ transplantation.
• •Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.
• •Received a live vaccine ≤ 28 days before first dose of study drug.
• •History of severe hypersensitivity reaction to any monoclonal antibody
• •Concurrent participation in another therapeutic clinical study
• •Pregnant or breastfeeding